You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCrizotinib
Accession NumberDB08865
TypeSmall Molecule
GroupsApproved
DescriptionCrizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Structure
Thumb
Synonyms
(R)-Crizotinib
C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
Crizotinibum
MET Tyrosine Kinase Inhibitor PF-02341066
PF 2341066
PF-2341066
External Identifiers
  • PF-02341066
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
XalkoriCapsule, hard250 mgOral usePfizer Ltd2012-10-23Not applicableEu
Xalkoricapsule250 mg/1oralPfizer Laboratories Div Pfizer Inc2011-08-26Not applicableUs
XalkoriCapsule, hard200 mgOral usePfizer Ltd2012-10-23Not applicableEu
Xalkoricapsule200 mg/1oralPfizer Laboratories Div Pfizer Inc2011-08-26Not applicableUs
XalkoriCapsule, hard200 mgOral usePfizer Ltd2012-10-23Not applicableEu
Xalkoricapsule200 mgoralPfizer Canada Inc2012-05-10Not applicableCanada
XalkoriCapsule, hard250 mgOral usePfizer Ltd2012-10-23Not applicableEu
Xalkoricapsule250 mgoralPfizer Canada Inc2012-05-10Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII53AH36668S
CAS number877399-52-5
WeightAverage: 450.337
Monoisotopic: 449.11854397
Chemical FormulaC21H22Cl2FN5O
InChI KeyInChIKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N
InChI
InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
IUPAC Name
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
SMILES
C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyrazolylpyridines. These are compounds containing a pyrazolylpyridine skeleton, which consists of a pyrazole linked (not fused) to a pyridine by a bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPyrazolylpyridines
Direct ParentPyrazolylpyridines
Alternative Parents
Substituents
  • 3-pyrazolylpyridine
  • 1,3-dichlorobenzene
  • Halobenzene
  • Fluorobenzene
  • Chlorobenzene
  • Aminopyridine
  • 4-aminopiperidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Primary aromatic amine
  • Piperidine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Heteroaromatic compound
  • Pyrazole
  • Azole
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
  • 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine (CHEBI:64310 )
Pharmacology
IndicationCrizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
PharmacodynamicsNot Available
Mechanism of actionCrizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d'Origine Nantais (RON). Abnormalities in the ALK gene caused by mutations or translocations may lead to expression of oncogenic fusion proteins. In patients with NSCLC, they have the EML4-ALK gene. Crizotinib inhibits ALK tyrosine kinase which ultimately results in decreased proliferation of cells that carry the genetic mutation and tumour survivability.
Related Articles
AbsorptionThe peak serum concentration was reached in 4 to 6 hours following an oral single-dose administration. Steady state was reached within 15 days when a dose of 250 mg twice daily was administered. The mean absolute bioavailability was 43% (range of 32% to 66%) following a single 250 mg oral dose. When taken with high-fat meal, AUC and Cmax were reduced.
Volume of distribution

Mean volume of distribution (Vss) is 1772 L following intravenous administration of a 50 mg dose. This high volume of distribution suggest extensive distribution into tissue from plasma.

Protein bindingCrizotinib is 91% bound to plasma protein. This is not affected by drug concentration.
Metabolism

Crizotinib is metabolized by CYP3A4 and CYP3A5 in which these enzymes mediates the O-dealkylation of the drug.

Route of eliminationFollowing the administration of a single 250 mg radiolabeled crizotinib dose to healthy subjects, 63% and 22% of the administered dose was recovered in feces and urine, respectively. Unchanged crizotinib represented approximately 53% and 2.3% of the administered dose in feces and urine, respectively.
Half lifePlasma terminal half-life, patients = 42 hours
Clearance

The mean apparent clearance (CL/F) of crizotinib was lower at steady state (60 L/hr) after 250 mg twice daily than that after a single 250 mg oral dose (100 L/hr), which was likely due to autoinhibition of CYP3A by crizotinib after multiple dosing.

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9721
Caco-2 permeable-0.5672
P-glycoprotein substrateSubstrate0.6938
P-glycoprotein inhibitor INon-inhibitor0.6713
P-glycoprotein inhibitor IIInhibitor0.7105
Renal organic cation transporterInhibitor0.5464
CYP450 2C9 substrateNon-substrate0.7545
CYP450 2D6 substrateNon-substrate0.7023
CYP450 3A4 substrateSubstrate0.6029
CYP450 1A2 substrateInhibitor0.6676
CYP450 2C9 inhibitorInhibitor0.5
CYP450 2D6 inhibitorNon-inhibitor0.8662
CYP450 2C19 inhibitorInhibitor0.6237
CYP450 3A4 inhibitorNon-inhibitor0.6301
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8676
Ames testNon AMES toxic0.5981
CarcinogenicityNon-carcinogens0.8018
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6581 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.643
hERG inhibition (predictor II)Inhibitor0.7877
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral200 mg
Capsuleoral200 mg/1
Capsuleoral250 mg/1
Capsuleoral250 mg
Capsule, hardOral use200 mg
Capsule, hardOral use250 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2517256 No2013-04-302024-02-26Canada
CA2577937 No2010-12-212025-08-15Canada
CA2578066 No2011-10-112025-08-15Canada
CA2632286 No2011-11-152026-11-23Canada
US7230098 No2005-08-262025-08-26Us
US7825137 No2007-05-122027-05-12Us
US7858643 No2009-10-082029-10-08Us
US8217057 No2009-11-062029-11-06Us
US8785632 No2005-03-012025-03-01Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.83 MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.00611 mg/mLALOGPS
logP3.82ALOGPS
logP3.57ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)10.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area77.99 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity128.43 m3·mol-1ChemAxon
Polarizability45.44 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Timm A, Kolesar JM: Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261. [PubMed:23686600 ]
  2. Forde PM, Rudin CM: Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2012 Jun;13(8):1195-201. doi: 10.1517/14656566.2012.688029. [PubMed:22594847 ]
External Links
ATC CodesL01XE16
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (279 KB)
MSDSDownload (105 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Crizotinib.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Crizotinib.
AcebutololAcebutolol may increase the bradycardic activities of Crizotinib.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Crizotinib.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Crizotinib.
AcetaminophenThe serum concentration of Crizotinib can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Crizotinib.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Crizotinib.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Crizotinib.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Crizotinib.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Crizotinib.
AlbendazoleThe serum concentration of Crizotinib can be increased when it is combined with Albendazole.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Crizotinib.
AldosteroneThe serum concentration of Crizotinib can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Crizotinib.
AlectinibThe serum concentration of Crizotinib can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Crizotinib.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Crizotinib.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Crizotinib.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Crizotinib.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Crizotinib.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Crizotinib.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Crizotinib.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Crizotinib.
AlosetronThe metabolism of Alosetron can be decreased when combined with Crizotinib.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Crizotinib.
AmantadineAmantadine may increase the QTc-prolonging activities of Crizotinib.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Crizotinib.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Crizotinib.
Aminohippuric acidThe serum concentration of Crizotinib can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Crizotinib.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Crizotinib.
AmiodaroneThe serum concentration of Crizotinib can be increased when it is combined with Amiodarone.
AmiodaroneCrizotinib may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Crizotinib.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Crizotinib.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Crizotinib.
AmlodipineThe serum concentration of Crizotinib can be increased when it is combined with Amlodipine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Crizotinib.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Crizotinib.
AmprenavirThe serum concentration of Crizotinib can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Crizotinib can be increased when it is combined with Amsacrine.
AnagrelideCrizotinib may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Crizotinib.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Crizotinib.
ApomorphineApomorphine may increase the QTc-prolonging activities of Crizotinib.
ApremilastThe metabolism of Apremilast can be decreased when combined with Crizotinib.
AprepitantThe serum concentration of Crizotinib can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Crizotinib.
ArformoterolArformoterol may increase the QTc-prolonging activities of Crizotinib.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Crizotinib.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Crizotinib.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Crizotinib.
Arsenic trioxideCrizotinib may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherCrizotinib may increase the QTc-prolonging activities of Artemether.
AsenapineCrizotinib may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Crizotinib.
AstemizoleThe serum concentration of Crizotinib can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Crizotinib can be increased when it is combined with Atazanavir.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Crizotinib.
AtenololThe serum concentration of Crizotinib can be increased when it is combined with Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Crizotinib.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Crizotinib.
AtorvastatinThe serum concentration of Crizotinib can be increased when it is combined with Atorvastatin.
AvanafilThe metabolism of Avanafil can be decreased when combined with Crizotinib.
AxitinibThe metabolism of Axitinib can be decreased when combined with Crizotinib.
AzelastineThe metabolism of Azelastine can be decreased when combined with Crizotinib.
AzelastineThe serum concentration of Crizotinib can be increased when it is combined with Azelastine.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Crizotinib.
AzithromycinThe serum concentration of Crizotinib can be increased when it is combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Crizotinib.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Crizotinib.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Crizotinib.
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Crizotinib.
BenzocaineThe serum concentration of Crizotinib can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Crizotinib.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Crizotinib.
BepridilThe serum concentration of Crizotinib can be increased when it is combined with Bepridil.
BeractantBeractant may increase the bradycardic activities of Crizotinib.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Crizotinib.
BetaxololBetaxolol may increase the bradycardic activities of Crizotinib.
BevacizumabBevacizumab may increase the cardiotoxic activities of Crizotinib.
BexaroteneThe serum concentration of Crizotinib can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Crizotinib.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Crizotinib.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Crizotinib.
BiperidenThe serum concentration of Crizotinib can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Crizotinib.
BisoprololBisoprolol may increase the bradycardic activities of Crizotinib.
BoceprevirThe serum concentration of Crizotinib can be increased when it is combined with Boceprevir.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Crizotinib.
BortezomibBortezomib may increase the QTc-prolonging activities of Crizotinib.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Crizotinib.
BosentanThe serum concentration of Crizotinib can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Crizotinib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Crizotinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Crizotinib.
BretyliumBretylium may increase the bradycardic activities of Crizotinib.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Crizotinib.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Crizotinib.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Crizotinib.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Crizotinib.
BromocriptineThe serum concentration of Crizotinib can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Crizotinib.
BudesonideThe metabolism of Budesonide can be decreased when combined with Crizotinib.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Crizotinib.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Crizotinib.
BuprenorphineThe serum concentration of Crizotinib can be increased when it is combined with Buprenorphine.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Crizotinib.
BuserelinBuserelin may increase the QTc-prolonging activities of Crizotinib.
BuspironeThe metabolism of Buspirone can be decreased when combined with Crizotinib.
BuspironeThe serum concentration of Crizotinib can be increased when it is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Crizotinib.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Crizotinib.
CabazitaxelThe serum concentration of Crizotinib can be increased when it is combined with Cabazitaxel.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Crizotinib.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Crizotinib.
CaffeineThe metabolism of Caffeine can be decreased when combined with Crizotinib.
CaffeineThe serum concentration of Crizotinib can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Crizotinib.
CalfactantCalfactant may increase the bradycardic activities of Crizotinib.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Crizotinib.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Crizotinib.
CanagliflozinThe serum concentration of Crizotinib can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Crizotinib can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Crizotinib can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Crizotinib can be decreased when it is combined with Carbamazepine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Crizotinib.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Crizotinib.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Crizotinib.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Crizotinib.
CarteololCarteolol may increase the bradycardic activities of Crizotinib.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Crizotinib.
CarvedilolThe serum concentration of Crizotinib can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Crizotinib can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Crizotinib.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Crizotinib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Crizotinib.
CeritinibCrizotinib may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Crizotinib can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Crizotinib.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Crizotinib.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Crizotinib.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Crizotinib.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Crizotinib.
ChloroquineThe serum concentration of Crizotinib can be increased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Crizotinib.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Crizotinib.
ChlorpromazineThe serum concentration of Crizotinib can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Crizotinib can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Crizotinib can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Crizotinib.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Crizotinib.
CholesterolThe serum concentration of Crizotinib can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Crizotinib can be decreased when it is combined with Cholic Acid.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Crizotinib.
CilazaprilThe serum concentration of Crizotinib can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Crizotinib.
CimetidineThe serum concentration of Crizotinib can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Crizotinib.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Crizotinib.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Crizotinib.
CiprofloxacinThe serum concentration of Crizotinib can be increased when it is combined with Ciprofloxacin.
CisaprideCrizotinib may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Crizotinib.
CitalopramCrizotinib may increase the QTc-prolonging activities of Citalopram.
CitalopramThe serum concentration of Crizotinib can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Crizotinib can be increased when it is combined with Clarithromycin.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Crizotinib.
ClemastineThe metabolism of Crizotinib can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Crizotinib.
ClobazamThe metabolism of Clobazam can be decreased when combined with Crizotinib.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Crizotinib.
ClofazimineThe serum concentration of Crizotinib can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Crizotinib.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Crizotinib.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Crizotinib.
ClomipramineClomipramine may increase the QTc-prolonging activities of Crizotinib.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Crizotinib.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Crizotinib.
ClonidineThe metabolism of Clonidine can be decreased when combined with Crizotinib.
ClonidineClonidine may increase the bradycardic activities of Crizotinib.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Crizotinib.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Crizotinib.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Crizotinib.
ClotrimazoleThe metabolism of Crizotinib can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Crizotinib.
ClozapineThe metabolism of Clozapine can be decreased when combined with Crizotinib.
CobicistatThe serum concentration of Crizotinib can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Crizotinib.
CocaineThe metabolism of Cocaine can be decreased when combined with Crizotinib.
CodeineThe metabolism of Codeine can be decreased when combined with Crizotinib.
ColchicineThe metabolism of Colchicine can be decreased when combined with Crizotinib.
ColchicineThe serum concentration of Crizotinib can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Crizotinib can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Crizotinib can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Crizotinib.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Crizotinib.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Crizotinib.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Crizotinib.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.
CyclosporineThe metabolism of Crizotinib can be decreased when combined with Cyclosporine.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Crizotinib.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Crizotinib.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Crizotinib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Crizotinib.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Crizotinib.
DaclatasvirThe serum concentration of Crizotinib can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Crizotinib can be increased when it is combined with Dactinomycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Crizotinib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Crizotinib.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Crizotinib.
DapsoneThe metabolism of Dapsone can be decreased when combined with Crizotinib.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Crizotinib.
DarunavirThe serum concentration of Crizotinib can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Crizotinib.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Crizotinib.
DasatinibThe serum concentration of Crizotinib can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Crizotinib.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Crizotinib.
DaunorubicinThe serum concentration of Crizotinib can be decreased when it is combined with Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Crizotinib.
DeferasiroxThe serum concentration of Crizotinib can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Crizotinib.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Crizotinib.
DelavirdineThe metabolism of Crizotinib can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Crizotinib.
DesipramineDesipramine may increase the QTc-prolonging activities of Crizotinib.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Crizotinib.
DesloratadineThe serum concentration of Crizotinib can be increased when it is combined with Desloratadine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Crizotinib.
DexamethasoneThe serum concentration of Crizotinib can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Crizotinib.
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Crizotinib.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Crizotinib.
DextromethorphanThe serum concentration of Crizotinib can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Crizotinib.
DiazepamThe metabolism of Diazepam can be decreased when combined with Crizotinib.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Crizotinib.
DiclofenacThe serum concentration of Crizotinib can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Crizotinib.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Crizotinib.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Crizotinib.
DigoxinDigoxin may decrease the cardiotoxic activities of Crizotinib.
DigoxinThe metabolism of Digoxin can be decreased when combined with Crizotinib.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Crizotinib.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Crizotinib.
DihydroergotamineThe metabolism of Crizotinib can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Crizotinib.
DiltiazemThe metabolism of Crizotinib can be decreased when combined with Diltiazem.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Crizotinib.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Crizotinib.
DipyridamoleThe serum concentration of Crizotinib can be increased when it is combined with Dipyridamole.
DisopyramideCrizotinib may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Crizotinib.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Crizotinib.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Crizotinib.
DofetilideCrizotinib may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Crizotinib.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Crizotinib.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Crizotinib.
DonepezilThe metabolism of Donepezil can be decreased when combined with Crizotinib.
DonepezilDonepezil may increase the bradycardic activities of Crizotinib.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Crizotinib.
DoxazosinThe serum concentration of Crizotinib can be increased when it is combined with Doxazosin.
DoxepinDoxepin may increase the QTc-prolonging activities of Crizotinib.
DoxepinThe metabolism of Doxepin can be decreased when combined with Crizotinib.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Crizotinib.
DoxorubicinThe serum concentration of Crizotinib can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Crizotinib can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Crizotinib.
DronedaroneCrizotinib may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Crizotinib can be decreased when combined with Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Crizotinib.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Crizotinib.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Crizotinib.
EfavirenzThe serum concentration of Crizotinib can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Crizotinib.
ElbasvirThe serum concentration of Crizotinib can be increased when it is combined with Elbasvir.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Crizotinib.
EliglustatCrizotinib may increase the QTc-prolonging activities of Eliglustat.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Crizotinib.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Crizotinib.
EnalaprilThe serum concentration of Crizotinib can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Crizotinib can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Crizotinib.
EpinastineThe metabolism of Epinastine can be decreased when combined with Crizotinib.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Crizotinib.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Crizotinib.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Crizotinib.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Crizotinib.
ErgonovineThe serum concentration of Crizotinib can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Crizotinib.
EribulinEribulin may increase the QTc-prolonging activities of Crizotinib.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Crizotinib.
ErythromycinThe metabolism of Crizotinib can be decreased when combined with Erythromycin.
EscitalopramCrizotinib may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Crizotinib can be decreased when it is combined with Eslicarbazepine acetate.
EsmololEsmolol may increase the bradycardic activities of Crizotinib.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Crizotinib.
EstazolamThe metabolism of Estazolam can be decreased when combined with Crizotinib.
EstradiolThe metabolism of Estradiol can be decreased when combined with Crizotinib.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Crizotinib.
EstramustineThe metabolism of Estramustine can be decreased when combined with Crizotinib.
EstramustineThe serum concentration of Crizotinib can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Crizotinib can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Crizotinib.
EstroneThe metabolism of Estrone can be decreased when combined with Crizotinib.
EstroneThe serum concentration of Crizotinib can be decreased when it is combined with Estrone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Crizotinib.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Crizotinib.
EthanolThe metabolism of Ethanol can be decreased when combined with Crizotinib.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Crizotinib.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Crizotinib.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Crizotinib.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Crizotinib.
EtoposideThe metabolism of Etoposide can be decreased when combined with Crizotinib.
EtoposideThe serum concentration of Crizotinib can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Crizotinib.
EtravirineThe serum concentration of Crizotinib can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Crizotinib.
EverolimusThe metabolism of Everolimus can be decreased when combined with Crizotinib.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Crizotinib.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Crizotinib.
EzogabineEzogabine may increase the QTc-prolonging activities of Crizotinib.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Crizotinib.
FamotidineFamotidine may increase the QTc-prolonging activities of Crizotinib.
FelbamateFelbamate may increase the QTc-prolonging activities of Crizotinib.
FelbamateThe metabolism of Felbamate can be decreased when combined with Crizotinib.
FelodipineThe metabolism of Felodipine can be decreased when combined with Crizotinib.
FelodipineThe serum concentration of Crizotinib can be increased when it is combined with Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Crizotinib.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Crizotinib.
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Crizotinib.
FexofenadineThe serum concentration of Crizotinib can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Crizotinib can be increased when it is combined with Fidaxomicin.
FinasterideThe metabolism of Finasteride can be decreased when combined with Crizotinib.
FingolimodFingolimod may increase the QTc-prolonging activities of Crizotinib.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Crizotinib.
FlecainideFlecainide may increase the QTc-prolonging activities of Crizotinib.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Crizotinib.
FluconazoleFluconazole may increase the QTc-prolonging activities of Crizotinib.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Crizotinib.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Crizotinib.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Crizotinib.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Crizotinib.
FluoxetineCrizotinib may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe serum concentration of Crizotinib can be increased when it is combined with Fluoxetine.
FlupentixolCrizotinib may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe serum concentration of Crizotinib can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Crizotinib can be increased when it is combined with Fluphenazine.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Crizotinib.
FlurazepamThe serum concentration of Crizotinib can be increased when it is combined with Flurazepam.
FlutamideThe metabolism of Flutamide can be decreased when combined with Crizotinib.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Crizotinib.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Crizotinib.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Crizotinib.
FluvoxamineThe metabolism of Crizotinib can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Crizotinib.
FosamprenavirThe metabolism of Crizotinib can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Crizotinib can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Crizotinib.
FosphenytoinThe serum concentration of Crizotinib can be decreased when it is combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Crizotinib.
Fusidic AcidThe serum concentration of Crizotinib can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Crizotinib.
GalantamineGalantamine may increase the QTc-prolonging activities of Crizotinib.
GalantamineThe metabolism of Galantamine can be decreased when combined with Crizotinib.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Crizotinib.
GefitinibThe serum concentration of Crizotinib can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Crizotinib.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Crizotinib.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Crizotinib.
GenisteinThe serum concentration of Crizotinib can be increased when it is combined with Genistein.
GlipizideThe metabolism of Glipizide can be decreased when combined with Crizotinib.
GlyburideThe metabolism of Glyburide can be decreased when combined with Crizotinib.
GlyburideThe serum concentration of Crizotinib can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Crizotinib can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Crizotinib.
Gramicidin DThe serum concentration of Crizotinib can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Crizotinib.
GranisetronThe metabolism of Granisetron can be decreased when combined with Crizotinib.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Crizotinib.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Crizotinib.
GrepafloxacinThe serum concentration of Crizotinib can be increased when it is combined with Grepafloxacin.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Crizotinib.
GuanfacineGuanfacine may increase the bradycardic activities of Crizotinib.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Crizotinib.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Crizotinib.
HaloperidolThe serum concentration of Crizotinib can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Crizotinib.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Crizotinib.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Crizotinib.
HistrelinHistrelin may increase the QTc-prolonging activities of Crizotinib.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Crizotinib.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Crizotinib.
HydrocortisoneThe serum concentration of Crizotinib can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Crizotinib.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Crizotinib.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Crizotinib.
IbandronateIbandronate may increase the QTc-prolonging activities of Crizotinib.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Crizotinib.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Crizotinib.
IbutilideCrizotinib may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Crizotinib can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Crizotinib resulting in a loss in efficacy.
IloperidoneCrizotinib may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Crizotinib.
ImatinibThe metabolism of Crizotinib can be decreased when combined with Imatinib.
ImipramineImipramine may increase the QTc-prolonging activities of Crizotinib.
ImipramineThe metabolism of Imipramine can be decreased when combined with Crizotinib.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Crizotinib.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Crizotinib.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Crizotinib.
IndapamideIndapamide may increase the QTc-prolonging activities of Crizotinib.
IndapamideThe metabolism of Indapamide can be decreased when combined with Crizotinib.
IndinavirThe serum concentration of Crizotinib can be increased when it is combined with Indinavir.
IndinavirThe metabolism of Indinavir can be decreased when combined with Crizotinib.
IndomethacinThe serum concentration of Crizotinib can be increased when it is combined with Indomethacin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Crizotinib.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Crizotinib.
IsavuconazoniumThe metabolism of Crizotinib can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Crizotinib.
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Crizotinib.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Crizotinib.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Crizotinib.
IsradipineIsradipine may increase the QTc-prolonging activities of Crizotinib.
IsradipineThe metabolism of Isradipine can be decreased when combined with Crizotinib.
ItraconazoleThe serum concentration of Crizotinib can be increased when it is combined with Itraconazole.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Crizotinib.
IvabradineIvabradine may increase the QTc-prolonging activities of Crizotinib.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Crizotinib.
IvacaftorThe serum concentration of Crizotinib can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Crizotinib.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Crizotinib.
IvermectinThe serum concentration of Crizotinib can be increased when it is combined with Ivermectin.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Crizotinib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Crizotinib.
KetamineThe metabolism of Ketamine can be decreased when combined with Crizotinib.
KetamineThe serum concentration of Crizotinib can be increased when it is combined with Ketamine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Crizotinib.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Crizotinib.
KetoconazoleThe serum concentration of Crizotinib can be increased when it is combined with Ketoconazole.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Crizotinib.
LabetalolLabetalol may increase the bradycardic activities of Crizotinib.
LacosamideCrizotinib may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Crizotinib.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Crizotinib.
LanreotideLanreotide may increase the bradycardic activities of Crizotinib.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Crizotinib.
LansoprazoleThe serum concentration of Crizotinib can be increased when it is combined with Lansoprazole.
LapatinibLapatinib may increase the QTc-prolonging activities of Crizotinib.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Crizotinib.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Crizotinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Crizotinib.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Crizotinib.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Crizotinib.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Crizotinib.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Crizotinib.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Crizotinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Crizotinib.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Crizotinib.
LevobunololLevobunolol may increase the bradycardic activities of Crizotinib.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Crizotinib.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Crizotinib.
LevofloxacinThe serum concentration of Crizotinib can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Crizotinib.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Crizotinib.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Crizotinib.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Crizotinib.
LevothyroxineThe serum concentration of Crizotinib can be decreased when it is combined with Levothyroxine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Crizotinib.
LidocaineThe serum concentration of Crizotinib can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Crizotinib.
LiothyronineThe serum concentration of Crizotinib can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Crizotinib can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Crizotinib can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Crizotinib.
LithiumLithium may increase the QTc-prolonging activities of Crizotinib.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Crizotinib.
LoperamideThe metabolism of Loperamide can be decreased when combined with Crizotinib.
LoperamideThe serum concentration of Crizotinib can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Crizotinib can be increased when it is combined with Lopinavir.
LopinavirCrizotinib may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Crizotinib.
LoratadineThe serum concentration of Crizotinib can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Crizotinib.
LosartanThe metabolism of Losartan can be decreased when combined with Crizotinib.
LosartanThe serum concentration of Crizotinib can be increased when it is combined with Losartan.
LovastatinThe metabolism of Crizotinib can be decreased when combined with Lovastatin.
LucinactantLucinactant may increase the bradycardic activities of Crizotinib.
LuliconazoleThe serum concentration of Crizotinib can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Crizotinib can be decreased when it is combined with Lumacaftor.
LumefantrineCrizotinib may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Crizotinib.
MacitentanThe metabolism of Macitentan can be decreased when combined with Crizotinib.
MalathionThe metabolism of Malathion can be decreased when combined with Crizotinib.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Crizotinib.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Crizotinib.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Crizotinib.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Crizotinib.
MebendazoleThe serum concentration of Crizotinib can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Crizotinib.
MefloquineMefloquine may increase the QTc-prolonging activities of Crizotinib.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Crizotinib.
Megestrol acetateThe serum concentration of Crizotinib can be increased when it is combined with Megestrol acetate.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Crizotinib.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Crizotinib.
MeprobamateThe serum concentration of Crizotinib can be increased when it is combined with Meprobamate.
MethadoneThe metabolism of Methadone can be decreased when combined with Crizotinib.
MethadoneThe serum concentration of Crizotinib can be increased when it is combined with Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Crizotinib.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Crizotinib.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Crizotinib.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Crizotinib.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Crizotinib.
MethyldopaMethyldopa may increase the bradycardic activities of Crizotinib.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Crizotinib.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Crizotinib.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Crizotinib.
MetipranololMetipranolol may increase the bradycardic activities of Crizotinib.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Crizotinib.
MetoprololThe serum concentration of Crizotinib can be increased when it is combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Crizotinib.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Crizotinib.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Crizotinib.
MianserinThe metabolism of Mianserin can be decreased when combined with Crizotinib.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Crizotinib.
MibefradilThe serum concentration of Crizotinib can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Crizotinib.
MiconazoleThe serum concentration of Crizotinib can be increased when it is combined with Miconazole.
MidazolamThe metabolism of Midazolam can be decreased when combined with Crizotinib.
MidazolamThe serum concentration of Crizotinib can be decreased when it is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Crizotinib.
MirabegronMirabegron may increase the QTc-prolonging activities of Crizotinib.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Crizotinib.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Crizotinib.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Crizotinib.
MitomycinThe serum concentration of Crizotinib can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Crizotinib can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Crizotinib can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Crizotinib.
ModafinilThe serum concentration of Crizotinib can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Crizotinib.
MoexiprilMoexipril may increase the QTc-prolonging activities of Crizotinib.
MontelukastThe metabolism of Montelukast can be decreased when combined with Crizotinib.
MorphineThe metabolism of Morphine can be decreased when combined with Crizotinib.
MorphineThe serum concentration of Crizotinib can be increased when it is combined with Morphine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Crizotinib.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Crizotinib.
NadololThe serum concentration of Nadolol can be increased when it is combined with Crizotinib.
NadololNadolol may increase the bradycardic activities of Crizotinib.
NafcillinThe serum concentration of Crizotinib can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Crizotinib.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Crizotinib.
NaltrexoneThe serum concentration of Crizotinib can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Crizotinib can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Crizotinib.
NebivololNebivolol may increase the bradycardic activities of Crizotinib.
NefazodoneThe serum concentration of Crizotinib can be increased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Crizotinib.
NelfinavirThe serum concentration of Crizotinib can be increased when it is combined with Nelfinavir.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Crizotinib.
NeostigmineThe serum concentration of Crizotinib can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Crizotinib can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Crizotinib can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Crizotinib.
NicardipineNicardipine may increase the QTc-prolonging activities of Crizotinib.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Crizotinib.
NicotineThe metabolism of Nicotine can be decreased when combined with Crizotinib.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Crizotinib.
NifedipineThe serum concentration of Crizotinib can be decreased when it is combined with Nifedipine.
NilotinibCrizotinib may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Crizotinib can be decreased when combined with Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Crizotinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Crizotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Crizotinib.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Crizotinib.
NisoldipineThe serum concentration of Crizotinib can be increased when it is combined with Nisoldipine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Crizotinib.
NitrazepamThe serum concentration of Crizotinib can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Crizotinib.
NitrendipineThe serum concentration of Crizotinib can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Crizotinib.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Crizotinib.
NorethisteroneThe serum concentration of Crizotinib can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Crizotinib.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Crizotinib.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Crizotinib.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Crizotinib.
OctreotideOctreotide may increase the QTc-prolonging activities of Crizotinib.
OctreotideCrizotinib may increase the bradycardic activities of Octreotide.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Crizotinib.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Crizotinib.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Crizotinib.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Crizotinib.
OlaparibThe metabolism of Crizotinib can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Crizotinib.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Crizotinib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Crizotinib.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Crizotinib.
OmeprazoleThe serum concentration of Crizotinib can be increased when it is combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Crizotinib.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Crizotinib.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Crizotinib.
OsimertinibThe serum concentration of Crizotinib can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Crizotinib.
OuabainOuabain may decrease the cardiotoxic activities of Crizotinib.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Crizotinib.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Crizotinib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Crizotinib.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Crizotinib.
OxytocinOxytocin may increase the QTc-prolonging activities of Crizotinib.
P-NitrophenolThe serum concentration of Crizotinib can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Crizotinib.
PaclitaxelThe serum concentration of Crizotinib can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Crizotinib can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Crizotinib.
PaliperidoneCrizotinib may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Crizotinib can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Crizotinib.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Crizotinib.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Crizotinib.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Crizotinib.
PantoprazoleThe serum concentration of Crizotinib can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Crizotinib.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Crizotinib.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Crizotinib.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Crizotinib.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Crizotinib.
ParoxetineParoxetine may increase the QTc-prolonging activities of Crizotinib.
PasireotidePasireotide may increase the QTc-prolonging activities of Crizotinib.
PasireotideCrizotinib may increase the bradycardic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Crizotinib.
PazopanibPazopanib may increase the QTc-prolonging activities of Crizotinib.
PenbutololPenbutolol may increase the bradycardic activities of Crizotinib.
PentamidinePentamidine may increase the QTc-prolonging activities of Crizotinib.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Crizotinib.
PentobarbitalThe serum concentration of Crizotinib can be decreased when it is combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Crizotinib.
PerflutrenPerflutren may increase the QTc-prolonging activities of Crizotinib.
PergolideThe metabolism of Pergolide can be decreased when combined with Crizotinib.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Crizotinib.
PerindoprilThe serum concentration of Crizotinib can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Crizotinib.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Crizotinib.
PethidineThe metabolism of Pethidine can be decreased when combined with Crizotinib.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Crizotinib.
PhenobarbitalThe serum concentration of Crizotinib can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Crizotinib.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Crizotinib.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Crizotinib.
PhenytoinThe serum concentration of Crizotinib can be decreased when it is combined with Phenytoin.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Crizotinib.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Crizotinib.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Crizotinib.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Crizotinib.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Crizotinib.
PindololPindolol may increase the bradycardic activities of Crizotinib.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Crizotinib.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Crizotinib.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Crizotinib.
Platelet Activating FactorThe serum concentration of Crizotinib can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Crizotinib.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Crizotinib.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Crizotinib.
PonatinibThe serum concentration of Crizotinib can be increased when it is combined with Ponatinib.
Poractant alfaCrizotinib may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe serum concentration of Crizotinib can be increased when it is combined with Posaconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Crizotinib.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Crizotinib.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Crizotinib.
PravastatinThe serum concentration of Crizotinib can be increased when it is combined with Pravastatin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Crizotinib.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Crizotinib.
PrazosinThe serum concentration of Crizotinib can be increased when it is combined with Prazosin.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Crizotinib.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Crizotinib.
PrednisoneThe serum concentration of Crizotinib can be increased when it is combined with Prednisone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Crizotinib.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Crizotinib.
PrimidoneThe serum concentration of Crizotinib can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Crizotinib can be increased when it is combined with Probenecid.
ProcainamideCrizotinib may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Crizotinib.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Crizotinib.
ProgesteroneThe serum concentration of Crizotinib can be decreased when it is combined with Progesterone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Crizotinib.
PromazinePromazine may increase the QTc-prolonging activities of Crizotinib.
PromazineThe metabolism of Promazine can be decreased when combined with Crizotinib.
PromethazinePromethazine may increase the QTc-prolonging activities of Crizotinib.
PromethazineThe metabolism of Promethazine can be decreased when combined with Crizotinib.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Crizotinib.
PropofolPropofol may increase the QTc-prolonging activities of Crizotinib.
PropofolThe metabolism of Propofol can be decreased when combined with Crizotinib.
PropranololThe metabolism of Propranolol can be decreased when combined with Crizotinib.
PropranololThe serum concentration of Crizotinib can be increased when it is combined with Propranolol.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Crizotinib.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Crizotinib.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Crizotinib.
QuazepamThe metabolism of Quazepam can be decreased when combined with Crizotinib.
QuercetinThe serum concentration of Crizotinib can be increased when it is combined with Quercetin.
QuetiapineCrizotinib may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Crizotinib.
QuinacrineThe serum concentration of Crizotinib can be increased when it is combined with Quinacrine.
QuinidineCrizotinib may increase the QTc-prolonging activities of Quinidine.
QuinidineThe serum concentration of Crizotinib can be increased when it is combined with Quinidine.
QuinineCrizotinib may increase the QTc-prolonging activities of Quinine.
QuinineThe serum concentration of Crizotinib can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Crizotinib.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Crizotinib.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Crizotinib.
RanitidineThe serum concentration of Crizotinib can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Crizotinib.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Crizotinib.
ReboxetineThe serum concentration of Crizotinib can be increased when it is combined with Reboxetine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Crizotinib.
RegorafenibThe serum concentration of Crizotinib can be increased when it is combined with Regorafenib.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Crizotinib.
ReserpineThe serum concentration of Crizotinib can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Crizotinib.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Crizotinib.
RifabutinThe serum concentration of Crizotinib can be decreased when it is combined with Rifabutin.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Crizotinib.
RifampicinThe serum concentration of Crizotinib can be decreased when it is combined with Rifampicin.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Crizotinib.
RifapentineThe serum concentration of Crizotinib can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Crizotinib.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Crizotinib.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Crizotinib.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Crizotinib.
RiociguatThe metabolism of Riociguat can be decreased when combined with Crizotinib.
RisperidoneRisperidone may increase the QTc-prolonging activities of Crizotinib.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Crizotinib.
RitonavirThe serum concentration of Crizotinib can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Crizotinib.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Crizotinib.
RivastigmineRivastigmine may increase the bradycardic activities of Crizotinib.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Crizotinib.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Crizotinib.
RolapitantThe serum concentration of Crizotinib can be increased when it is combined with Rolapitant.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Crizotinib.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Crizotinib.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Crizotinib.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Crizotinib.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Crizotinib.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Crizotinib.
RuxolitinibRuxolitinib may increase the bradycardic activities of Crizotinib.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Crizotinib.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Crizotinib.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Crizotinib.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Crizotinib.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Crizotinib.
SaquinavirThe serum concentration of Crizotinib can be increased when it is combined with Saquinavir.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Crizotinib.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Crizotinib.
ScopolamineThe serum concentration of Crizotinib can be increased when it is combined with Scopolamine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Crizotinib.
SelegilineThe serum concentration of Crizotinib can be increased when it is combined with Selegiline.
SelexipagThe metabolism of Selexipag can be decreased when combined with Crizotinib.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Crizotinib.
SertindoleThe metabolism of Sertindole can be decreased when combined with Crizotinib.
SertralineSertraline may increase the QTc-prolonging activities of Crizotinib.
SertralineThe metabolism of Sertraline can be decreased when combined with Crizotinib.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Crizotinib.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Crizotinib.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Crizotinib.
SildenafilThe metabolism of Crizotinib can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Crizotinib.
SiltuximabThe serum concentration of Crizotinib can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Crizotinib can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Crizotinib.
SimvastatinThe serum concentration of Crizotinib can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Crizotinib.
SirolimusThe serum concentration of Crizotinib can be decreased when it is combined with Sirolimus.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Crizotinib.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Crizotinib.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Crizotinib.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Crizotinib.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Crizotinib.
SorafenibSorafenib may increase the QTc-prolonging activities of Crizotinib.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Crizotinib.
SotalolCrizotinib may increase the QTc-prolonging activities of Sotalol.
SotalolSotalol may increase the bradycardic activities of Crizotinib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Crizotinib.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Crizotinib.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Crizotinib.
SpironolactoneThe serum concentration of Crizotinib can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Crizotinib can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Crizotinib can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Crizotinib can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Crizotinib can be decreased when it is combined with Streptozocin.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Crizotinib.
SufentanilSufentanil may increase the bradycardic activities of Crizotinib.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Crizotinib.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Crizotinib.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Crizotinib.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Crizotinib.
SulfinpyrazoneThe serum concentration of Crizotinib can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleCrizotinib may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Crizotinib can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Crizotinib can be increased when it is combined with Sumatriptan.
SunitinibSunitinib may increase the QTc-prolonging activities of Crizotinib.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Crizotinib.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Crizotinib.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Crizotinib.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Crizotinib.
TacrineThe serum concentration of Crizotinib can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Crizotinib.
TacrolimusThe serum concentration of Crizotinib can be decreased when it is combined with Tacrolimus.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Crizotinib.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Crizotinib.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Crizotinib.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Crizotinib.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Crizotinib.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Crizotinib.
Taurocholic AcidThe serum concentration of Crizotinib can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Crizotinib.
TelaprevirThe serum concentration of Crizotinib can be increased when it is combined with Telaprevir.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Crizotinib.
TelavancinTelavancin may increase the QTc-prolonging activities of Crizotinib.
TelithromycinThe serum concentration of Crizotinib can be increased when it is combined with Telithromycin.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Crizotinib.
TelmisartanThe serum concentration of Crizotinib can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Crizotinib.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Crizotinib.
TemsirolimusThe serum concentration of Crizotinib can be increased when it is combined with Temsirolimus.
TeniposideThe metabolism of Teniposide can be decreased when combined with Crizotinib.
TerazosinThe serum concentration of Crizotinib can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Crizotinib.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Crizotinib.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Crizotinib.
TerfenadineThe serum concentration of Crizotinib can be increased when it is combined with Terfenadine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Crizotinib.
TesmilifeneThe serum concentration of Crizotinib can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Crizotinib.
TestosteroneThe serum concentration of Crizotinib can be increased when it is combined with Testosterone.
TetrabenazineCrizotinib may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Crizotinib.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Crizotinib.
ThioridazineCrizotinib may increase the QTc-prolonging activities of Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Crizotinib.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Crizotinib.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Crizotinib.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Crizotinib.
TicagrelorThe serum concentration of Crizotinib can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Crizotinib can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Crizotinib.
TimololTimolol may increase the bradycardic activities of Crizotinib.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Crizotinib.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Crizotinib.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Crizotinib.
TizanidineTizanidine may increase the QTc-prolonging activities of Crizotinib.
TizanidineCrizotinib may increase the bradycardic activities of Tizanidine.
TocilizumabThe serum concentration of Crizotinib can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Crizotinib.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Crizotinib.
TolterodineTolterodine may increase the QTc-prolonging activities of Crizotinib.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Crizotinib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Crizotinib.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Crizotinib.
ToremifeneCrizotinib may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Crizotinib.
TramadolThe metabolism of Tramadol can be decreased when combined with Crizotinib.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Crizotinib.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Crizotinib.
TrazodoneTrazodone may increase the QTc-prolonging activities of Crizotinib.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Crizotinib.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Crizotinib.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Crizotinib.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Crizotinib.
TriazolamThe metabolism of Triazolam can be decreased when combined with Crizotinib.
TrifluoperazineThe serum concentration of Crizotinib can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Crizotinib can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Crizotinib.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Crizotinib.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Crizotinib.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Crizotinib.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Crizotinib.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Crizotinib.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Crizotinib.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Crizotinib.
TroleandomycinThe serum concentration of Crizotinib can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be decreased when combined with Crizotinib.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Crizotinib.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Crizotinib.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Crizotinib.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Crizotinib.
VandetanibCrizotinib may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Crizotinib.
VardenafilVardenafil may increase the QTc-prolonging activities of Crizotinib.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Crizotinib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Crizotinib.
VemurafenibCrizotinib may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Crizotinib.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Crizotinib.
VerapamilThe metabolism of Crizotinib can be decreased when combined with Verapamil.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Crizotinib.
VilanterolVilanterol may increase the QTc-prolonging activities of Crizotinib.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Crizotinib.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Crizotinib.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Crizotinib.
VinblastineThe serum concentration of Crizotinib can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Crizotinib.
VincristineThe serum concentration of Crizotinib can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Crizotinib.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Crizotinib.
VinorelbineThe serum concentration of Crizotinib can be increased when it is combined with Vinorelbine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Crizotinib.
VoriconazoleThe serum concentration of Crizotinib can be increased when it is combined with Voriconazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Crizotinib.
VorinostatVorinostat may increase the QTc-prolonging activities of Crizotinib.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Crizotinib.
WarfarinThe metabolism of Warfarin can be decreased when combined with Crizotinib.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Crizotinib.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Crizotinib.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Crizotinib.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Crizotinib.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Crizotinib.
ZileutonThe metabolism of Zileuton can be decreased when combined with Crizotinib.
ZimelidineThe serum concentration of Crizotinib can be increased when it is combined with Zimelidine.
ZiprasidoneCrizotinib may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Crizotinib can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Crizotinib.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Crizotinib.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Crizotinib.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Crizotinib.
ZuclopenthixolCrizotinib may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • When given with a high-fat meal, AUC and Cmax were reduced by 14%. Despite this, crizotinib may be given with or without food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost...
Gene Name:
ALK
Uniprot ID:
Q9UM73
Molecular Weight:
176440.535 Da
References
  1. Forde PM, Rudin CM: Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2012 Jun;13(8):1195-201. doi: 10.1517/14656566.2012.688029. [PubMed:22594847 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream sig...
Gene Name:
MET
Uniprot ID:
P08581
Molecular Weight:
155540.035 Da
References
  1. Forde PM, Rudin CM: Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2012 Jun;13(8):1195-201. doi: 10.1517/14656566.2012.688029. [PubMed:22594847 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Timm A, Kolesar JM: Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261. [PubMed:23686600 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Timm A, Kolesar JM: Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261. [PubMed:23686600 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Timm A, Kolesar JM: Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261. [PubMed:23686600 ]
Comments
comments powered by Disqus
Drug created on March 28, 2013 11:22 / Updated on September 26, 2016 02:14